Should I buy or sell Catalyst Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CPRX shares. View CPRX analyst ratings or view top-rated stocks .

What is Catalyst Pharmaceuticals' stock price target for 2024?

4 analysts have issued 12-month price objectives for Catalyst Pharmaceuticals' stock. Their CPRX share price targets range from $24.00 to $27.00. On average, they anticipate the company's share price to reach $24.75 in the next twelve months. This suggests a possible upside of 71.5% from the stock's current price. View analysts price targets for CPRX or view top-rated stocks among Wall Street analysts .

How have CPRX shares performed in 2023?

Catalyst Pharmaceuticals' stock was trading at $18.60 at the start of the year. Since then, CPRX stock has decreased by 22.4% and is now trading at $14.43. View the best growth stocks for 2023 here .

When is Catalyst Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024. View our CPRX earnings forecast .

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) released its quarterly earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, meeting the consensus estimate of ($0.26). The biopharmaceutical company had revenue of $102.69 million for the quarter, compared to the consensus estimate of $100.17 million. Catalyst Pharmaceuticals had a net margin of 17.81% and a trailing twelve-month return on equity of 19.32%.

What ETFs hold Catalyst Pharmaceuticals' stock?

ETFs with the largest weight of Catalyst Pharmaceuticals (NASDAQ:CPRX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) , Invesco Biotechnology & Genome ETF (PBE) , Janus Henderson Small Cap Growth Alpha ETF (JSML) , SPDR S&P Biotech ETF (XBI) , Invesco S&P SmallCap Health Care ETF (PSCH) , ERShares NextGen Entrepreneurs ETF (ERSX) , Invesco S&P SmallCap 600 Pure Growth ETF (RZG) and ALPS Medical Breakthroughs ETF (SBIO) .

What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX) , Sorrento Therapeutics (SRNE) , Amarin (AMRN) , Inovio Pharmaceuticals (INO) , Corbus Pharmaceuticals (CRBP) , Micron Technology (MU) , Verastem (VSTM) , Exelixis (EXEL) , Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD) .

Who are Catalyst Pharmaceuticals' major shareholders?

Catalyst Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Northern Trust Corp (1.35%), Jacobs Levy Equity Management Inc. (1.23%), LSV Asset Management (1.16%), Invesco Ltd. (0.96%), Charles Schwab Investment Management Inc. (0.86%) and American Century Companies Inc. (0.84%). Insiders that own company stock include Alicia Grande , Brian Elsbernd, Carmen Jeffrey Del, David S Tierney, Donald A Denkhaus, Gary Ingenito , Patrick J Mcenany , Philip H Coelho , Preethi Sundaram and Steve Miller . View institutional ownership trends .

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Positive News SentimentPositive News

Catalyst Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CPRX)

$14.43

+0.38 (+2.70%)

(As of 11/30/2023 ET)

Compare

Today's Range: $14.06
▼
$14.51
50-Day Range: $11.69
▼
$14.43
52-Week Range: $11.09
▼
$22.11

Volume: 1.18 million shs
Average Volume: 1.07 million shs
Market Capitalization: $1.54 billion

P/E Ratio: 27.75
Dividend Yield: N/A
Price Target: $24.75

Catalyst Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 71.5% Upside
$24.75 Price Target
Short Interest: Bearish
7.27% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.99
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: 42.50%
From $1.60 to $2.28 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.74 out of 5 stars

Medical Sector

70th out of 948 stocks

Pharmaceutical Preparations Industry

23rd out of 448 stocks

3.5

Analyst's Opinion

Consensus Rating
Catalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $24.75, Catalyst Pharmaceuticals has a forecasted upside of 71.5% from its current price of $14.43.
Amount of Analyst Coverage
Catalyst Pharmaceuticals has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
7.27% of the float of Catalyst Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Catalyst Pharmaceuticals has a short interest ratio ("days to cover") of 5.5.
Change versus previous month
Short interest in Catalyst Pharmaceuticals has recently increased by 3.74%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Catalyst Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Catalyst Pharmaceuticals does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Catalyst Pharmaceuticals has received a 52.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Amifampridine" and "Clinical research services for physiological diseases " products. See details.
Environmental Sustainability
The Environmental Impact score for Catalyst Pharmaceuticals is -1.99.

3.3

News and Social Media Coverage

News Sentiment
Catalyst Pharmaceuticals has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Catalyst Pharmaceuticals this week, compared to 5 articles on an average week.
Search Interest
Only 18 people have searched for CPRX on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.
MarketBeat Follows
12 people have added Catalyst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Catalyst Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
12.10% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
77.27% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Catalyst Pharmaceuticals are expected to grow by 42.50% in the coming year, from $1.60 to $2.28 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Catalyst Pharmaceuticals is 27.75, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 113.11.
Price to Earnings Ratio vs. Sector
The P/E ratio of Catalyst Pharmaceuticals is 27.75, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 101.63.
Price to Book Value per Share Ratio
Catalyst Pharmaceuticals has a P/B Ratio of 4.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Catalyst Pharmaceuticals Stock (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

CPRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CPRX Stock News Headlines

November 16, 2023 | finance.yahoo.com

Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference

November 10, 2023 | finance.yahoo.com

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q3 2023 Earnings Call Transcript

December 1, 2023 | Edge On The Street (Ad)

Is Gold Really Boring?

Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.

November 8, 2023 | benzinga.com

Recap: Catalyst Pharmaceuticals Q3 Earnings

November 8, 2023 | finance.yahoo.com

Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update

November 5, 2023 | finance.yahoo.com

Catalyst Pharmaceuticals Inc (CN2.DU)

November 2, 2023 | finance.yahoo.com

Amylyx Pharmaceuticals, Inc. (AMLX) Earnings Expected to Grow: What to Know Ahead of Q3 Release

November 2, 2023 | finance.yahoo.com

Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®

December 1, 2023 | Edge On The Street (Ad)

Is Gold Really Boring?

October 31, 2023 | seekingalpha.com

Catalyst Pharmaceuticals: Agamree Approval Selloff A Long-Term Buying Opportunity

October 30, 2023 | finance.yahoo.com

Institutional owners may take dramatic actions as Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) recent 4.2% drop adds to one-year losses

October 28, 2023 | finanznachrichten.de

Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE

October 23, 2023 | finance.yahoo.com

Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023

October 20, 2023 | marketwatch.com

Catalyst Pharmaceuticals Director to Succeed Retiring CEO

October 19, 2023 | bizjournals.com

Pharmaceutical company names former AstraZeneca exec new CEO, founder to retire

October 19, 2023 | finance.yahoo.com

Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer

October 16, 2023 | finance.yahoo.com

Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida

October 14, 2023 | finance.yahoo.com

Those who invested in Catalyst Pharmaceuticals (NASDAQ:CPRX) three years ago are up 291%

October 13, 2023 | markets.businessinsider.com

Catalyst Pharma Reports FDA Acceptance Of SNDA For FIRDAPSE

October 13, 2023 | finance.yahoo.com

Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE®

September 27, 2023 | finance.yahoo.com

If EPS Growth Is Important To You, Catalyst Pharmaceuticals (NASDAQ:CPRX) Presents An Opportunity

September 21, 2023 | marketwatch.com

Catalyst Pharmaceuticals Inc. stock falls Thursday, still outperforms market

September 18, 2023 | finance.yahoo.com

Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference

September 9, 2023 | seekingalpha.com

Catalyst Pharmaceuticals launches $500M mixed shelf offering - filing

September 8, 2023 | finance.yahoo.com

Why Is Catalyst (CPRX) Down 14% Since Last Earnings Report?

September 8, 2023 | stocknews.com

September Buy, Sell or Hold for This Pharma Sock: Catalyst Pharmaceuticals (CPRX)

September 6, 2023 | finance.yahoo.com

Unraveling the Future of Catalyst Pharmaceuticals Inc (CPRX): A Deep Dive into Key Metrics

See More Headlines

Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2023
Today: 12/01/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/20/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CPRX
CUSIP: N/A
CIK: 1369568
Web: www.catalystpharma.com
Phone: (305) 420-3200
Fax: 305-529-0933
Employees: 82
Year Founded: 2002

Price Target and Rating

Average Stock Price Target: $24.75
High Stock Price Target: $27.00
Low Stock Price Target: $24.00
Potential Upside/Downside: +71.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.52
Trailing P/E Ratio: 27.75
Forward P/E Ratio: 9.02
P/E Growth: N/A
Net Income: $83.08 million
Net Margins: 17.81%
Pretax Margin: 23.20%
Return on Equity: 19.32%
Return on Assets: 16.00%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.32
Quick Ratio: 3.17

Sales & Book Value

Annual Sales: $214.20 million
Price / Sales: 7.18
Cash Flow: $0.83 per share
Price / Cash Flow: 17.34
Book Value: $3.27 per share
Price / Book: 4.41

Miscellaneous

Outstanding Shares: 106,610,000
Free Float: 93,711,000
Market Cap: $1.54 billion
Optionable: Optionable
Beta: 1.08

Social Links

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Patrick J. McEnany (Age 76)
Co-Founder, Chairman, President & CEO
Comp: $1.2M
Ms. Alicia Grande C.M.A. (Age 52)
CPA, Chief Accounting Officer, VP, Treasurer & CFO
Comp: $667.91k
Dr. Steven R. Miller Ph.D. (Age 61)
COO & Chief Scientific Officer
Comp: $809.03k
Dr. Gary Ingenito M.D. (Age 67)
Ph.D., Chief Medical & Regulatory Officer
Comp: $751.85k
Mr. Jeffrey Del Carmen (Age 52)
Chief Commercial Officer
Comp: $711.7k
Ms. Mary Coleman
VP & Head of Investor Relations
Mr. Brian Elsbernd J.D. (Age 59)
Chief Compliance Officer & Chief Legal Officer
Comp: $311.42k
Mr. Pete Curry Sr.
Vice President of Sales
Dr. Stanley Iyadurai M.D.
Ph.D., Senior Vice President of Medical Affairs & Drug Discovery
Dr. Preethi Sundaram Ph.D. (Age 47)
Chief Strategy Officer
Comp: $511.25k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CPRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Catalyst Pharmaceuticals stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CPRX shares.
View CPRX analyst ratings or view top-rated stocks.
What is Catalyst Pharmaceuticals' stock price target for 2024?: 4 analysts have issued 12-month price objectives for Catalyst Pharmaceuticals' stock. Their CPRX share price targets range from $24.00 to $27.00. On average, they anticipate the company's share price to reach $24.75 in the next twelve months. This suggests a possible upside of 71.5% from the stock's current price.
View analysts price targets for CPRX or view top-rated stocks among Wall Street analysts.
How have CPRX shares performed in 2023?: Catalyst Pharmaceuticals' stock was trading at $18.60 at the start of the year. Since then, CPRX stock has decreased by 22.4% and is now trading at $14.43.
View the best growth stocks for 2023 here.
When is Catalyst Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our CPRX earnings forecast.
How were Catalyst Pharmaceuticals' earnings last quarter?: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) released its quarterly earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, meeting the consensus estimate of ($0.26). The biopharmaceutical company had revenue of $102.69 million for the quarter, compared to the consensus estimate of $100.17 million. Catalyst Pharmaceuticals had a net margin of 17.81% and a trailing twelve-month return on equity of 19.32%.

What ETFs hold Catalyst Pharmaceuticals' stock?: ETFs with the largest weight of Catalyst Pharmaceuticals (NASDAQ:CPRX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Invesco Biotechnology & Genome ETF (PBE), Janus Henderson Small Cap Growth Alpha ETF (JSML), SPDR S&P Biotech ETF (XBI), Invesco S&P SmallCap Health Care ETF (PSCH), ERShares NextGen Entrepreneurs ETF (ERSX), Invesco S&P SmallCap 600 Pure Growth ETF (RZG) and ALPS Medical Breakthroughs ETF (SBIO).
What other stocks do shareholders of Catalyst Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).
Who are Catalyst Pharmaceuticals' major shareholders?: Catalyst Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Northern Trust Corp (1.35%), Jacobs Levy Equity Management Inc. (1.23%), LSV Asset Management (1.16%), Invesco Ltd. (0.96%), Charles Schwab Investment Management Inc. (0.86%) and American Century Companies Inc. (0.84%). Insiders that own company stock include Alicia Grande, Brian Elsbernd, Carmen Jeffrey Del, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller.
View institutional ownership trends.
How do I buy shares of Catalyst Pharmaceuticals?: Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CPRX) was last updated on 12/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial